.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,361,499

« Back to Dashboard

Claims for Patent: 8,361,499

Title:Controlled release hydrocodone formulations
Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.
Inventor(s): Oshlack; Benjamin (New York, NY), Huang; Hua-Pin (Englewood Cliffs, NJ), Masselink; John K. (Old Tappan, NJ), Tonelli; Alfred P. (Congers, NY)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Application Number:13/535,996
Patent Claims: 1. A solid oral controlled-release dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof and a controlled release material selected from the group consisting of hydrophobic polymers, hydrophilic polymers, gums, protein derived materials, waxes, shellac, oils and mixtures thereof, the dosage form providing a controlled release of the hydrocodone or the pharmaceutically acceptable salt thereof for a time period of from 8 to at least about 24 hours, an in-vitro release rate of hydrocodone or a pharmaceutically acceptable salt thereof, when measured by the USP Basket Method at 100 rpm in 900 ml aqueous buffer at a pH of between 1.6 and 7.2 at 37.degree. C., of from 0% to about 35% at 1 hour, from about 10% to about 70% at 4 hours, from about 20% to about 75% at 8 hours, from about 30% to about 80% at 12 hours, from about 40% to about 90% at 18 hours, and greater than about 60% at 24 hours, and, after administration to a human patient or a population of patients and after the maximum plasma concentration of the hydrocodone is reached, providing a relatively flat serum plasma profile of the hydrocodone meaning that the plasma level of the hydrocodone provides a C.sub.24/C.sub.max ratio of about 0.55 to about 1.0.

2. The dosage form of claim 1, wherein said administration is first administration.

3. The dosage form of claim 1, which provides a therapeutic plasma concentration of the hydrocodone for a period of time of about 12 hours or longer and a W.sub.50 for the hydrocodone of between 4 and 22 hours.

4. The dosage form of claim 1, which provides a C.sub.24/C.sub.max ratio of 0.55 to 0.75.

5. The dosage form of claim 1, wherein the controlled release material is incorporated into a matrix along with the hydrocodone or the pharmaceutically acceptable salt thereof, or the controlled release material is applied as a sustained release coating over a substrate comprising the hydrocodone or the pharmaceutically acceptable salt thereof.

6. The dosage form of claim 5, wherein the controlled release material is incorporated into the matrix along with the hydrocodone or the pharmaceutically acceptable salt thereof.

7. The dosage form of claim 6, wherein the matrix comprises an alkylcellulose, a hydroxyalkylcellulose, or mixtures thereof.

8. The dosage form of claim 7, wherein the matrix further comprises a hydrophobic material having a melting point from about 30 to about 200.degree. C.

9. The dosage form of claim 7, wherein the matrix further comprises a fatty acid, a fatty alcohol, a glyceryl ester of fatty acid, a wax, a polyalkylene glycol, or a mixture of any of the foregoing materials.

10. The dosage form of claim 9, wherein the matrix comprises the glyceryl ester of a fatty acid.

11. The dosage form of claim 9, wherein the matrix is coated with a coating comprising (i) an alkylcellulose, (ii) an acrylic polymer, or (iii) a mixture of the alkylcellulose and the acrylic polymer.

12. The dosage form of claim 6, wherein said matrix comprises a granule comprising a water soluble hydroxyalkyl cellulose and the hydrocodone or the pharmaceutically acceptable salt thereof.

13. The dosage form of claim 12, wherein the granule is coated with a coating comprising (i) an alkylcellulose, (ii) an acrylic polymer, or (iii) or a mixture of the alkylcellulose and the acrylic polymer.

14. The dosage form of claim 13, wherein the coating further comprises a water insoluble material.

15. The dosage form of claim 14, wherein the water insoluble material is a wax.

16. The dosage form of claim 1 which is provided as a multiparticulate formulation.

17. The dosage form of claim 1 which is provided as spheroids.

18. The dosage form of claim 1 which is provided as an osmotic dosage form.

19. The dosage form of claim 18 which comprises a single layer or bilayer core comprising the hydrocodone or the pharmaceutically acceptable salt thereof; an expandable polymer; a semipermeable membrane surrounding the core; and a passageway disposed in the semipermeable membrane for sustained release of the hydrocodone or the pharmaceutically acceptable salt thereof.

20. The dosage form of claim 17, wherein the spheroids have a diameter of between 0.1 mm and 2.5 mm.

21. The dosage form of claim 17, wherein a portion of the spheroids provides a controlled release of the hydrocodone or the pharmaceutically acceptable salt thereof and a portion of the spheorids provides an immediate release of the hydrocodone or the pharmaceutically acceptable salt thereof.

22. The dosage form of claim 21, wherein the spheroids providing the controlled release of the hydrocodone comprise hydrocodone or the pharmaceutically acceptable salt thereof coated with the coating comprising the controlled release material.

23. The dosage form of claim 22, wherein the controlled release material in the coating comprises an acrylic resin.

24. The dosage form of claim 23, wherein the coating further comprises one or more release-modifying agents.

25. The dosage form of claim 23, wherein the coating further comprises an erosion-promoting agent.

26. The dosage form of claim 25, wherein the erosion-promotion agent is starch.

27. The dosage form of claim 22 further comprising talc.

28. The dosage form of claim 22 further comprising a surfactant.

29. The dosage form of claim 16 further comprising povidone.

30. The dosage form of claim 21, comprising a capsule comprising the spheroids providing the controlled release of the hydrocodone or the pharmaceutically acceptable salt thereof and the spheroids providing the immediate release of the hydrocodone or the pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc